HR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER
Clinical trials for HR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER trials appear
Sign up with your email to follow new studies for HR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for advanced breast cancer: drug combo targets resistant tumors
Disease control Recruiting nowThis study tests a new oral drug called SPH4336 combined with hormone therapy (letrozole or fulvestrant) in people with a common type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after prior treatment. About 254 participants will receive either the dru…
Matched conditions: HR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER
Phase: PHASE2, PHASE3 • Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Tiny drug particles aim to target tough breast, ovarian, and endometrial cancers
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called BL0175, a nano-medicine designed to deliver treatment directly into tumors. It is for postmenopausal women with advanced or metastatic hormone-receptor-positive breast, ovarian, or endometrial cancer that has progresse…
Matched conditions: HR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER
Phase: PHASE1 • Sponsor: Shanghai Best-Link Bioscience, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC